MentionFox
Home › Acquisitions › InMed Pharmaceuticals Inc.
Completed acquisition · SEC Form 8-K, Item 2.01

Mentari acquired by InMed Pharmaceuticals Inc.

Before you sign with, sell to or invest in InMed Pharmaceuticals Inc.

MentionFox check on InMed Pharmaceuticals Inc.: only 2 sources on file so far (checked 13 November 2026). Run a full check before you rely on it. mentionfox.com/c/acquisitions/inmed-pharmaceuticals-mentari-2026-11-06

  • Note: Layoff plan disclosed Mar 2026 (filing)

Check InMed Pharmaceuticals Inc. before you sign, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about InMed Pharmaceuticals Inc.?

From InMed Pharmaceuticals Inc.'s Form 8-K of 2026-11-10, quoted and linked below.

Mentari was acquired by InMed Pharmaceuticals Inc. on November 6, 2026, according to the Form 8-K InMed Pharmaceuticals Inc. filed with the SEC. The filing states a price of $490 million. The deal closed under a securities purchase agreement dated May 19, 2026. It is the only completed acquisition InMed Pharmaceuticals Inc. reported under Item 2.01 in the last twelve months (Form 8-K, November 10, 2026).

InMed Pharmaceuticals Inc. agreed to acquire Mentari on Nov 10. 2 companies announced an acquisition this week, 1 had other signals.

Companies in an acquisition this week, and the deal. Before you unlock: the company, the deal and what is inside. After: every way we found to reach the company, and anyone a source names. A team joining the buyer is labelled only when the filing itself says so.

InMed Pharmaceuticals Inc.agreed to acquire Mentari
Liberty Capital Corp/NVagreed to acquire Q Gateway Intermediate Holdings, LLC
Check one company free All companies that announced an acquisition this week

Competing with, selling to or investing in InMed Pharmaceuticals Inc. after this deal? See the free Snapshot first.

Free to see. No signup.

InMed Pharmaceuticals Inc. completed its acquisition of Mentari on 2026-11-06, according to the Form 8-K InMed Pharmaceuticals Inc. filed with the SEC on 2026-11-10. The filing states a price of $490 million.

AcquirerInMed Pharmaceuticals Inc.
AcquiredMentari
Completed2026-11-06
Price stated in the filing$490 million
Reported byInMed Pharmaceuticals Inc. (INM), the buyer
FilingForm 8-K, filed 2026-11-10

Want the whole picture on InMed Pharmaceuticals Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on InMed Pharmaceuticals Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on InMed Pharmaceuticals Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    2 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

What the filing says

On November 6, 2026, First Merger Sub merged with and into Mentari, with Mentari continuing as a wholly owned subsidiary of the Company and the surviving corporation of the merger (the " First Merger "), and immediately thereafter, Mentari merged with and into Second Merger Sub, with Second Merger Sub being the surviving entity of the merger (the " Second Merger ," and together with the First Merger, the " Merger ").

How much did InMed Pharmaceuticals Inc. pay for Mentari?

Financing Transaction In connection with the Merger, Mentari entered into a securities purchase agreement, dated as of May 19, 2026, which agreement was subsequently amended on July 22, 2026 (as amended, the " Securities Purchase Agreement "), with certain institutional and accredited investors (the " Financing Investors "), pursuant to which such investors purchased, immediately prior to the First Merger, 215,042,178 shares of Mentari Common Stock and 7,317,328 Mentari Pre-Funded Warrants (the " PIPE Securities "), for an aggregate purchase price of approximately $490.0 million, which includes $52.7 million of principal and accrued interest under convertible notes previously issued by Menta

More from the filing

On November 6, 2026 (the " Closing Date "), Mentari Therapeutics, Inc., a Nevada corporation (formerly known as InMed Pharmaceuticals Inc.) (prior to the Closing Date, unless context otherwise requires, " InMed " and, after the Closing Date, the " Company "), consummated the previously announced business combination (the " Closing ") pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 19, 2026, which agreement was subsequently amended on July 6, 2026 (as amended, the " Merger Agreement "), by and among InMed, Indigo Merger Sub Corp., a Delaware corporation
Prior to the Closing, on November 4, 2026, following the annual general and special meeting of InMed shareholders, InMed (i) effected a consolidation of its outstanding common shares, no par value (the " InMed Common Shares "), at a ratio of one post-consolidation share for every ten pre-consolidation shares (the " Reverse Stock Split "), (ii) changed its name from "InMed Pharmaceuticals Inc." to "Mentari Therapeutics, Inc." (the " Name Change ") and (iii) altered its notice of articles and articles to designate 4,013 of its authorized but undesignated preferred shares as "Series A Non-Voting
On the Closing Date and prior to the Closing, as further described in Item 3.03 of this Current Report on Form 8-K, InMed redomesticated from the Province of British Columbia, Canada to the State of Nevada by way of a continuation out of British Columbia under the Business Corporations Act (British Columbia) (the " BCBCA ") and a domestication in Nevada pursuant to Section 92A.270 of the Nevada Revised Statutes (the " NRS ") (the " Redomestication ").

Quoted from InMed Pharmaceuticals Inc.'s Form 8-K.

This is the only completed acquisition InMed Pharmaceuticals Inc. reported under Item 2.01 in the last twelve months.

Selling to InMed Pharmaceuticals Inc., or weighing an offer there?

Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.

Order Full Report on InMed Pharmaceuticals Inc.
Not ready to order?

Look up InMed Pharmaceuticals Inc. first. Finding the company and seeing how much is on record uses no credits.

Look up InMed Pharmaceuticals Inc.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.

Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.

More on InMed Pharmaceuticals Inc.

Cite this page

Permanent URL: https://mentionfox.com/acquisitions/inmed-pharmaceuticals-mentari-2026-11-06
Last updated 2026-11-13
Primary record: SEC filing 1 · SEC filing 2
Mentari acquired by InMed Pharmaceuticals Inc. for $490 million: completed 2026-11-06. MentionFox, 2026-11-13. https://mentionfox.com/acquisitions/inmed-pharmaceuticals-mentari-2026-11-06